[en] Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID). A once-daily prolonged-release formulation (Tacrolimus QD) has been developed that may improve adherence and impart long-lasting graft protection. This study compared the pharmacokinetics (PK) of tacrolimus in de novo kidney transplant patients treated with Tacrolimus QD or Tacrolimus BID. A 6-week, open-label, randomized comparative study was conducted in centers in Europe and Australia. Eligible patients received Tacrolimus QD or Tacrolimus BID. PK profiles were obtained following the first tacrolimus dose (day 1), and twice under steady-state conditions. As secondary objectives, efficacy and safety parameters were also evaluated. Sixty-six patients completed all PK profiles (34 Tacrolimus QD, 32 Tacrolimus BID). Mean AUC(0-24) of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than Tacrolimus BID (232 and 361 ng.h/mL, respectively), but was comparable by day 4. There was a good correlation and a similar relationship between AUC(0-24) and C(min) for both formulations. Efficacy and safety data were also comparable over the 6-week period. Tacrolimus QD can be administered once daily in the morning on the basis of the same systemic exposure and therapeutic drug monitoring concept as Tacrolimus BID.
Disciplines :
Surgery
Author, co-author :
Wlodarczyk, Z.
Squifflet, Jean-Paul ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Gaston RS, Hudson SL, Ward M, Jones P, Macon R. Late renal allograft loss: Noncompliance masquerading as chronic rejection. Transplant Proc 1999 31 (Suppl. 4A 21S 23S.
Matas AJ, Humar A, Gillingham KJ et al. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002 62 : 704 714.
Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of non-adherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004 77 : 769 789.
Weng FL, Israni AK, Joffe MM et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005 16 : 1839 1848.
Ichimaru N, Kakuta Y, Abe T et al. Treatment adherence in renal transplant recipients: A questionnaire survey on immunosuppressants. Transplant Proc 2008 40 : 1362 1365.
Scott L, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003 63 : 1247 1297.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004 43 : 623 653.
Wallemacq P, Armstrong VW, Brunet M et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European Consensus Conference. Ther Drug Monit 2009 31 : 139 152.
Alloway R, Steinberg S, Khahil K et al. Conversion of stable kidney transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified-release tacrolimus-based regimen. Transplant Proc 2005 37 : 867 870. (Pubitemid 40590728)
Florman S, Alloway R, Kalayoglu M et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005 37 : 1211 1213. (Pubitemid 40590839)
Alloway R, Vanhaecke J, Undre N, For the Modified Release Tacrolimus Heart Study Group. Conversion of stable heart transplant recipients from twice-daily Prograf to once-daily modified-release tacrolimus. Transpl Int 2005 18 (Suppl 1 75 (Abstract PO-083).
Alak AM, Moy S, Cook M et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. J Pharm Biomed Anal 1997 16 : 7 13.
van Duijnhoven E, Christiaans M, Schafer A, Undre N, van Hooff J. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998 30 : 1266 1267.
van Duijnhoven E, Christiaans M, Schafer A, Undre N, Stevenson P, van Hooff J. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc 1998 30 : 1268 1270.
Mendonza A, Zahir H, Gohh R, Akhlaghi F. Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007 29 : 391 398.